Iovance Biotherapeutics, Inc. IOVA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s accounts receivable?
- Iovance Biotherapeutics, Inc. (IOVA) reported accounts receivable of $81.76M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s accounts receivable changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accounts receivable increased by 15.3% year-over-year, from $70.94M to $81.76M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accounts receivable?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s accounts receivable has grown at a 4206.8% compound annual growth rate (CAGR), from $151K to $280.09M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.